Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 4, 2004, Pages 967-971

  Hofer, Cristina B ^a,b   Schechter, Mauro ^a   Harrison, Lee H ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Brazil; CD4+ lymphocyte; HIV RNA; HIV viral load

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BRAZIL; DEVELOPED COUNTRY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HIV-1; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PUBLIC HEALTH PRACTICE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 3242692399     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408010-00011     Document Type: Article

References (16)

1. Piot P. Global AIDS epidemic: time to turn the tide. Science. 2000;288:2176-2178.
2. Boletim Epidemiológico - Coordenaçãao Nacional de DST/AIDS. Governo Brasileiro. 2000.
3. Galvao J. Access to antiretroviral drugs in Brazil. Lancet. 2002;360:1862-1865.
4. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
5. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-410.
6. Kitchen CM, Kitchen SG, Dubin JA, et al. Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis. 2001;33:466-472.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
8. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
9. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S112-S117.
10. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
11. Mezzaroma I, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS. 1999;13:1187-1193.
12. Gao X, Nau DP, Rosenbluth SA, et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care. 2000;12:387-398.
13. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:267-273.
14. Carmody ER, Diaz T, Starling P, et al. An evaluation of antiretroviral HIV/AIDS treatment in Rio de Janeiro public clinic. Trop Med Int Health. 2003;5:378-385.
15. Halkitis PN, Parsons JT, Wolitski RJ, et al. Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care. 2003;15:89-102.
16. Hecht FM, Robert GM, Petropoulos CJ, et al. Brief report: sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. New Engl J Med. 1998;339:307-311.